Human Anti-HLA-A2 PBF Recombinant Antibody (clone D12) (CAT#: FAMAB-0598WJ)
This product is a human monoclonal antibody that is specific for HLA-A2 papillomavirus binding factor (PBF). This antibody can be used in a variety of applications, such as ELISA, WB, FC, Inhib.
Specific Inquiry
ELISA
Figure 1 ELISA screening of the specific binders of 94 scFv clones reacting with biotinylated HLA-A*02:01·PBF A2.2 peptide complex.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 2 FACS analysis of scFv-hIgG1.
T2 cells were pulsed with the indicated peptides and stained with each scFv-hIgG1 at a concentration of 10 μg/ml. BB7.2 was used to detect expression of HLA-A2 molecules.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
SPR
Figure 3 Surface plasmon resonance analysis.
Biotinylated HLA-A*02:01·PBF A2.2 peptide complex (C) or HLA-A*02:01·HIV-A2 peptide complex (D) was immobilized on the sensor tip as the target.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
ELISA
Figure 4 ELISA screening of the reactivity of D12 scFv-hIgG against various biotinylated HLA-A*02:01·peptide complexes.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 5 FACS analysis of reactivity of D12 scFv-hIgG1 (1 mg/ml) and D12 scFv multimer (10 μg/ml) against T2 cells pulsed with the indicated peptides.
%MFI increase is indicated. T2 without peptide was used as the negative control. A more than 20.0% MFI increase is indicated by underlining.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 6 FACS analysis of reactivity of D12 scFv-hIgG1 (1 mg/ml) and D12 scFv multimer (10 μg/ml) against T2 cells pulsed with the indicated peptides.
%MFI increase is indicated. T2 without peptide was used as the negative control. A more than 20.0% MFI increase is indicated by underlining.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 7 FACS analysis of the reactivity of the D12 scFv multimer (3 μg/ml) with sarcoma cell lines and primary culture cells.
Osteosarcoma cell line U2OS (A*02:01/A*3201, PBF+), OS2000 (A*2402, PBF+), KIKU (A*0206/A*2402, PBF+), HOS (A*02:11, PBF+), Saos-2 (A*02:01/A*24:02, PBF+), malignant fibrous histiocytoma cell line MFH2003 (A*2402, PBF−), and primary culture of osteosarcoma (Primary OS; A*02:01, PBF+) were used as target cells. A more than 20.0% MFI increase is indicated by underlining. The expression status of HLA-A2·PBF A2.2 peptide complex was graded as follows: strong (≥100% MFI increase), weak (≥20% but <100% MFI increase), and none (<20% MFI increase).
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 8 Tetramer staining of oligoclonal CTL line 5A9 directed to HLA-A*02:01·PBF A2.2 peptide before and after positive selection.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
ELISA
Figure 9 CTL response against U2OS cells assessed by ELISA.
Tetramer-positive cells after enrichment were used as the responder.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
Inhib
Figure 10 Inhibition effect of scFv-hIgG1 on CTL response.
scFv D12-hIgG1 and irrelevant scFv D11-hIgG1 were used as blocking antibodies.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
Specifications
- Host Species
- Human
- Derivation
- Phage Display Library
- Type
- Human IgG
- Specificity
- HLA-A2 papillomavirus binding factor (PBF)
- Species Reactivity
- Human
- Clone
- D12
- Applications
- ELISA, WB, FC, Inhib
Product Property
- Purity
- >95% as determined by SDS-PAGE
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- HLA-A2 PBF
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "HLA-A2 PBF"
Select a product category from the dropdown menu below to view related products.
Please select product type
IgG Antibody Products
| CAT | Product Name | Application | Type |
|---|---|---|---|
| FAMAB-0596WJ | Human Anti-HLA-A2 PBF Recombinant Antibody (clone G3) | ELISA, WB, FC, Inhib | Human IgG |
| FAMAB-0597WJ | Human Anti-HLA-A2 PBF Recombinant Antibody (clone H7) | ELISA, WB, FC, Inhib | Human IgG |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for FAMAB-0598WJ. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: WB, ELISA, IP, FC, FuncS, Neut, IF
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: ELISA, WB, BLI, SPR
Application: WB, ELISA, FuncS
-1.jpg)
-1.png)
Application: WB, ELISA
Application: ELISA, PD, Activ, PK, Stim
Application: Neut, ELISA, WB, SPR, IF, EM
-1.jpg)
Application: ELISA, WB
-1.png)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
